Rema (Rao) Chaari

majority of tumors in our classification system were described and well documented prior to being also confirmed as having molecular drivers. For sure, molecular testing has helped clarify boundaries, but the classification system has expanded not contracted, with only a

🎥 In this #CytoVideo, @tarik_elsheikh explains how correlation of AUS, AUS:M, and ROM with molecular results can offer a robust framework for QA. 🔗 #OpenAccess article: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… 🔗 Full video: youtu.be/2SI3mzIBULg @CLEClinicLabs @CleClinicMD @Raodyisms

New and #OpenAccess! | Molecular testing and other metrics in thyroid cytology as quality-assurance measures in evaluating variation among pathologists in the diagnosis of atypia of undetermined significance acsjournals.onlinelibrary.wiley.com/doi/full/10.10… #CytoPath @Raodyisms @erikacytogal @ENT_Path

Congratulations to @elsheikhtarik and @Raodyisms for their comprehensive look at #QA in #thyroid #cytology. In case of #TLDR, see Table 3 to see how *your* lab compares! @GokozanMD @MichiyaNishino @CancerCytopath acsjournals.onlinelibrary.wiley.com/doi/full/10.10…

Outstanding grand rounds by @KMirza on the virtual renaissance of pathology education at @CCFPathRes 👏👏👏 #PathX #PathTwitter

This review covers all relevant aspects of #telecytology for ROSE, including digital pathology options, operators, validation, quality assurance, reimbursement, and recommendations from professional organizations. 🌹 acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @MDAndersonNews #CytoPath

@TRUMP_ARMY_ A

🚨 BREAKING: The new Florida law that allows for the DEATH PENALTY for adults who rape children under the age of 12 is now in effect. DO YOU SUPPORT THIS? A. YES B. NO

@pepeheffernan @AnupamaArya12 @Histopatolomon @edusqo @IvanaKholova @ariabdullah1978 @DanGrahamMD @medannabel @smlungpathguy @TotalCytopath @padmapathology1 SMARC A4 deficient tumors.

CC367. EBUS-TBNA of mediastinal nodes in an old woman with an extra pulmonary known tumor. Rhabdoid cells: abundant, dense cytoplasm occupied by filaments that pushes the nucleus. Discohesive; usually big nucleoli. This is not a melanoma, so think of other "usual rhabdoids"

📊 The Area Under the Curve (AUC) is a single number that shows how well a model can tell categories apart. It combines sensitivity (finding true positives) and specificity (avoiding false positives) into one overall score. A perfect model has an AUC of 1.0—no missed diagnoses, no false alarms. The higher the AUC, the more accurate and reliable the model is across all threshold settings. Think of it as the model’s “diagnostic precision” score!

@pepeheffernan @kriyer68 @DrBMcGinn @goziemnweke @DrGeeONE @kis_lorand @DrRanasaleh @HubertLauMD @OKCPathguy @TotalCytopath @Quique_rs @MAHoureih @smlungpathguy @Histopatolomon Ameloblastoma

CC361. FNA of a nodule in the cheek in a woman with previous history of oropharyngeal squamous cell carcinoma. More images below. I will give you a hint: not its typical location @kriyer68 @DrBMcGinn @goziemnweke

If you decide to seek a second opinion for a life altering diagnosis, I highly recommend that you have your original pathology diagnosis, when applicable, also reviewed. At many institutions this is (and should be) standard practice.

@JosephMisdraji What a great moment this is for you! I am so excited for your new ventures and I can’t wait for my turn 😉 enjoy the time!!

Happy Easter. I thought I would take this opportunity to announce that I am retiring from pathology at the end of this academic year. I have had a great career but it’s time to find joy pursuing other interests. I wish you all the best in your careers. Joe

An amazing issue!

PIRO is very cool, developed by Scott and used by many in our department. Please check it out!

We built a fast web-based application for searching pathology reports. Works especially well with Epic data. Contact me if you want to learn more. #Pathology Manuscript Link: doi.org/10.1016/j.jpi.…

@Vik_deshpandeMD Crucial to this approach is vastly overstating the value of NGS and targeted therapy. How many low grade neoplasms with a fusion do we need and how does it help the patient when they are all treated exactly the same?

Very true—but patients are aspirational, and so are their clinicians. People want the best, and the WHO has positioned itself as the gold standard in tumor classification. I’ve seen families willing to spend a lifetime’s savings on a single genetic test, just to give their child a shot at the best treatment. That’s how much weight the WHO carries. Which is why it’s deeply troubling that so much of its current framework is based on low-quality evidence and personal opinion. That’s not just poor science—it’s unfair.

@Vik_deshpandeMD I couldn't agree more! The WHO blue books, over the years, have become more glossy, hyper-specialized, and genetically obsessive; they now read like love letters to billion-dollar biotech firms. Problem is, the rest of the world isn’t reading along. Because we can't.

Controversial but crucial: The new WHO Blue Books heavily rely on molecular diagnostics, tools inaccessible to up to 80% of the world’s population. Instead of addressing global inequality, they risk deepening it. Radical, inclusive change is urgently needed.

The @PapSociety Executive Board had a productive meeting at #USCAP2025. Huge thanks to @AzizaNassar2 for her incredible leadership as the president and to our committee members for their dedication! @DiagnosticCyto @AzizaNassar2 @PoonamVohra3 @Baskotacytopath @IACytology